🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We understand the critical need for innovation and effective treatments in #COPD. Learn more about our progress and commitment to help patients breathe easier: gsk.to/4hRmgHh

Advances in technology are transforming cancer treatments – and the lives of patients with cancer. Here, Hesham Abdullah, GSK’s Global Head of Oncology R&D, discusses the leaps forward his team has made, and their ambitions for the future: gsk.to/3YcIyvY

GSK welcomes the ambition and urgency of yesterday’s announcement by the UK Government on health data and clinical trials. Find out more: gsk.to/44fJGmn

COPD exacerbations can cause changes to lung tissue which can accumulate over time leading to irreversible lung damage. We are ambitious for people living with COPD and have developed the COPD Exacerbation Recognition Tool to support them. Read more: gsk.to/4cn25Qh

In a recent interview with Bloomberg in London, our CEO, Emma Walmsley, discussed GSK’s progress, including our further improved long-term outlook for more than £40bn sales by 2031 and increased investment in R&D,

#News for #Investors and #Media The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed one of our blood cancer therapies. More information for media and investors: gsk.com/en-gb/

#News for #investors and #media: Two of our vaccines have received new recommendations from the US Advisory Committee on Immunization Practices (ACIP). These recommendations will be reviewed for official adoption. Learn more: gsk.com/en-gb/

We’re announcing our Q1 2025 results tomorrow at 0700 BST, 0200 EST. $GSK

#Investors: Join our CEO Emma Walmsley and other members of our leadership team for our Q1 2025 results webcast at 12:00 BST, 07:00 EST. $GSK

Explore the key highlights from our Q1 2025 performance. More information for media and investors: gsk.to/42TtzIS. $GSK

#News for #investors and #media: Today we have announced the full results of a phase III trial of one of our biologics in patients with chronic obstructive pulmonary disease (COPD) have been published in the New England Journal of Medicine. Learn more at: gsk.to/3Gz5YpG

#News for #investors and #media: At #ATS2025, we’ll be presenting data from 40+ abstracts on our work to redefine the future of respiratory care. Learn more: gsk.to/4cYZHQf

“It took 35 years to even get to the point where malaria vaccines are available. And now we’re excited to be researching a second-generation vaccine”. Katie Ewer, GSK Malaria Vaccine Project Leader explains to The Telegraph that our research aims to work at a different stage of

The race against malaria is on – find out why, and how, we’re accelerating research to help #ChangeTheTrajectory of the disease, here 👇 gsk.com/en-gb/behind-t…

Years of innovation have expanded the menu of preventative medicines available but science alone isn’t enough to make sure people have access to them. Here, Heidi Larson, anthropologist and co-founder of the Global Listening Project, explains why 👇 gsk.to/4m5ohD4

#News for #investors and #media: New data has been presented at #EASL2025 on our research into cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease. More information: gsk.to/4572tke

Congratulations to our CEO Emma Walmsley on being named in the 2025 #TIME100HEALTH list, which recognises the most influential leaders in health each year. See the full list here: gsk.to/4iRvtzG #Time100